ZK-93426

ZK-93426

Names
IUPAC name ethyl 5-​isopropoxy-​4-​methyl-​9H-​β-​carboline-​3-​carboxylate
Other names ZK-93426; ethyl 4-methyl-5-propan-2-yloxy-9H-pyrido[5,4-b]indole-3-carboxylate
Identifiers
CAS Number	89592-45-0 Y
3D model (JSmol)	Interactive image
ChemSpider	103086 N
IUPHAR/BPS	4347
PubChem CID	115210
InChI InChI=1S/C18H20N2O3/c1-5-22-18(21)17-11(4)15-13(9-19-17)20-12-7-6-8-14(16(12)15)23-10(2)3/h6-10,20H,5H2,1-4H3 N Key: VMDUABMKBUKKPG-UHFFFAOYSA-N N InChI=1/C18H20N2O3/c1-5-22-18(21)17-11(4)15-13(9-19-17)20-12-7-6-8-14(16(12)15)23-10(2)3/h6-10,20H,5H2,1-4H3 Key: VMDUABMKBUKKPG-UHFFFAOYAG
SMILES CCOC(=O)C1=NC=C2C(=C1C)C3=C(N2)C=CC=C3OC(C)C
Properties
Chemical formula	C18H20N2O3
Molar mass	314.336 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

ZK-93426 (ethyl-5-isopropoxy-4-methyl-beta-carboline-3-carboxylate) is a drug from the beta-carboline family. It acts as a weak partial inverse agonist of benzodiazepine receptors,^[1] meaning that it causes the opposite effects to the benzodiazepine class of drugs and has anxiogenic properties,^[2] although unlike most benzodiazepine antagonists it is not a convulsant and actually has weak anticonvulsant effects.^[3] In human tests it produced alertness, restlessness and feelings of apprehension, and reversed the effect of the benzodiazepine lormetazepam.^[4][5] It was also shown to produce nootropic effects^[6][7] and increased release of acetylcholine.^[8][9]

See also

• ZK-93423

References

1. ↑ Camerman, A; Mastropaolo, D; Hempel, A; Camerman, N (2005). "Ethyl 5-isopropoxy-4-methyl-beta-carboline-3-carboxylate: structural determinants of benzodiazepine-receptor antagonism". Acta Crystallographica C. 61 (Pt 4): o265–6. PMID 15805647. doi:10.1107/S0108270105005457. 
2. ↑ File, SE; Pellow, S; Jensen, LH (1986). "Actions of the beta-carboline ZK 93426 in an animal test of anxiety and the holeboard: interactions with Ro 15-1788". Journal of neural transmission. 65 (2): 103–14. PMID 3009709. doi:10.1007/BF01256486. 
3. ↑ Jensen, LH; Petersen, EN; Braestrup, C; Honoré, T; Kehr, W; Stephens, DN; Schneider, H; Seidelmann, D; Schmiechen, R (1984). "Evaluation of the beta-carboline ZK 93 426 as a benzodiazepine receptor antagonist". Psychopharmacology. 83 (3): 249–56. PMID 6089247. doi:10.1007/BF00464789. 
4. ↑ Dorow, R; Duka, T; Höller, L; Sauerbrey, N (1987). "Clinical perspectives of beta-carbolines from first studies in humans". Brain Research Bulletin. 19 (3): 319–26. PMID 2890423. doi:10.1016/0361-9230(87)90100-6. 
5. ↑ Duka, T; Goerke, D; Dorow, R; Höller, L; Fichte, K (1988). "Human studies on the benzodiazepine receptor antagonist beta-carboline ZK 93 426: antagonism of lormetazepam's psychotropic effects". Psychopharmacology. 95 (4): 463–71. PMID 2905500. doi:10.1007/bf00172956. 
6. ↑ Duka, T; Edelmann, V; Schütt, B; Dorow, R (1988). "Beta-carbolines as tools in memory research: human data with the beta-carboline ZK 93426". Psychopharmacology series. 6: 246–60. PMID 3064085. doi:10.1007/978-3-642-73288-1_18. 
7. ↑ Duka, T; Ott, H; Rohloff, A; Voet, B (1996). "The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills". Psychopharmacology. 123 (4): 361–73. PMID 8867876. doi:10.1007/BF02246647. 
8. ↑ Moore, H; Sarter, M; Bruno, JP (1992). "Age-dependent modulation of in vivo cortical acetylcholine release by benzodiazepine receptor ligands". Brain Research. 596 (1–2): 17–29. PMID 1334777. doi:10.1016/0006-8993(92)91527-L. 
9. ↑ Moore, H; Sarter, M; Bruno, JP (1993). "Bidirectional modulation of stimulated cortical acetylcholine release by benzodiazepine receptor ligands". Brain Research. 627 (2): 267–74. PMID 8298971. doi:10.1016/0006-8993(93)90330-P.